Comparison of repaglinide and glimepiridein type2 diabetes: combination with DPP-4 inhibitors, vildagliptin and linaglipti
Not Applicable
- Conditions
- Type 2 diabetes mellitus
- Registration Number
- JPRN-UMIN000010446
- Lead Sponsor
- Yokohama City University Medical Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
Not provided
Exclusion Criteria
1)severe ketosis, diabetic coma within 6 months 2)severe infection, before operation, severe trauma 3)severe hepatic dysfunction 4)or severe renal dysfunction (SCr:more than 2.0mg/dl or eGFR less than 30) 5)pregnacy 6)Allergy for vildagliptin, linagliptin, repaglinide and glimepiride 7)Patients judged by the investigator to be ineligible for some other reason
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Reduction rate of postprandial glucose after treatment with repaglinide or glimepiride
- Secondary Outcome Measures
Name Time Method 1)Achievment rate of <7.0% at 4 months 2)Achievement rate of <7.0% at 8months 3)Renal function 4)glycemic control 5)lipid control 6)Achievement rate of <6.5%,<180mg/dl of PPG